Tag: efficacy
Efficacy of the AstraZeneca coronavirus vaccine against the B.1.351 South African Variant
Study conclusions: A two-dose regimen of the ChAdOx1 nCoV-19 [AstraZeneca] vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 [South Africa ] variant. More...
Pfizer coronavirus vaccine may be less effective in people with obesity
The Pfizer/BioNTech vaccine may be less effective in people with obesity, data suggests. More...
Johnson and Johnson vaccine has a 72% overall efficacy rate in the US and 64% in South Africa
The Johnson and Johnson vaccine had a 72 percent overall efficacy rate in the United States and 64 percent in South Africa, where a highly contagious variant emerged in the fall and is now driving most cases. More...
Single Pfizer vaccine shot 90 per cent effective after 21 days
A single dose of the Pfizer vaccine provides “very high” protection from Covid-19 after 21 days – without a ‘top up’ dose in the recommended time frame, according to a new study from the University of East Anglia. More...
The effectiveness of the first dose of BNT162.b2 [Pfizer-Biontech] vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
“We demonstrated an effectiveness of 51% of BNT162b2 [Pfizer-Biontech] vaccine against SARS-CoV-2 infection 13-24 days after immunization with the first dose. More...
Novavax vaccine works well except on N501Y.V2 South Africa variant
An early analysis in Britain found that the Novavax vaccine had an efficacy rate of nearly 90 percent. More...
Israel’s coronavirus czar says first dose less effective than Pfizer indicated
Israel’s coronavirus czar Nachman Ash has reportedly said the first dose of Pfizer’s vaccine provides less protection against COVID-19 than the US pharmaceutical firm had initially indicated it would, and cautioned that it may not protect against new strains of the virus.
Sinovac coronavirus vaccine “significantly less effective than what previous data suggested”
The São Paulo-based Butantan Institute – which is running final-stage clinical trials for CoronaVac, manufactured by Beijing-based Sinovac – submitted new data to Brazil’s health regulator on Tuesday, listing an efficacy rate of 50.4 per cent. More...